Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib

被引：356

作者：

Cataldo, Vince D. ^{[1
,2
]}

Gibbons, Don L. ^{[3
]}

Perez-Soler, Roman ^{[4
]}

Quintas-Cardama, Alfonso ^{[3
]}

机构：

[1] Louisiana State Univ, Dept Hematol & Oncol, Hlth Sci Ctr, Baton Rouge, LA 70805 USA

[2] Hematol Oncol Clin, Baton Rouge, LA USA

[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[4] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2011年 / 364卷 / 10期

关键词：

EPIDERMAL-GROWTH-FACTOR; PHASE-III TRIAL; PREVIOUSLY TREATED PATIENTS; FACTOR-RECEPTOR; ACQUIRED-RESISTANCE; T790M MUTATIONS; SUPPORTIVE CARE; EGFR MUTATIONS; CARBOPLATIN; PACLITAXEL;

D O I：

10.1056/NEJMct0807960

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 64-year-old woman who has never smoked receives the diagnosis of stage I adenocarcinoma of the lung and undergoes right upper lobectomy. One year later, bone and liver metastases develop. She is treated with carboplatin, paclitaxel, and bevacizumab, but progressive bone metastases are noted after 6 weeks of therapy. An oncologist recommends the initiation of erlotinib therapy. Copyright © 2011 Massachusetts Medical Society.

引用

页码：947 / 955

页数：9

共 53 条

[1]

[Anonymous], IRESSA GEFITINIB PAC

[2]

[Anonymous], 2003, P AM SOC CLIN ONCOL

[3]

[Anonymous], TARCEVA ERLOTINIB PA

[4]

[Anonymous], MULT S THOR ONC CHIC

[5] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[6] MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].

Bean, James ;

Brennan, Cameron ;

Shih, Jin-Yuan ;

Riely, Gregory ;

Viale, Agnes ;

Wang, Lu ;

Chitale, Dhananjay ;

Motoi, Noriko ;

Szoke, Janos ;

Broderick, Stephen ;

Balak, Marissa ;

Chang, Wen-Cheng ;

Yu, Chong-Jen ;

Gazdar, Adi ;

Pass, Harvey ;

Rusch, Valerie ;

Gerald, William ;

Huang, Shiu-Feng ;

Yang, Pan-Chyr ;

Miller, Vincent ;

Ladany, Marc ;

Yang, Chih-Hsin ;

Pao, William .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937

[7] Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results [J].

Boone, Susan L. ;

Rademaker, Alfred ;

Liu, Dachao ;

Pfeiffer, Carmen ;

Mauro, David J. ;

Lacouture, Mario E. .

ONCOLOGY, 2007, 72 (3-4) :152-159

[8] Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer [J].

Choong, Nicholas W. ;

Mauer, Ann M. ;

Haraf, Daniel J. ;

Lester, Eric ;

Hoffman, Philip C. ;

Kozloff, Mark ;

Lin, Shang ;

Dancey, Janet E. ;

Szeto, Livia ;

Grushko, Tatyana ;

Olopade, Olufunmilayo I. ;

Salgia, Ravi ;

Vokes, Everett E. .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (09) :1003-1011

[9] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Mitsudomi, Tetsuya ;

Song, Youngchul ;

Hyland, Courtney ;

Park, Joon Oh ;

Lindeman, Neal ;

Gale, Christopher-Michael ;

Zhao, Xiaojun ;

Christensen, James ;

Kosaka, Takayuki ;

Holmes, Alison J. ;

Rogers, Andrew M. ;

Cappuzzo, Federico ;

Mok, Tony ;

Lee, Charles ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

SCIENCE, 2007, 316 (5827) :1039-1043

[10] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

← 1 2 3 4 5 6 →